100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R41CA243722
Award Date
9/2/20
Completion Date
11/30/21
Dollars Obligated
$327K
Overview
Activity
3
Transactions
3
Subawards
Similar Awards
Federal Agency
National Cancer Institute
Awardee
Endectra LLC (EX6HANR4NX67)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Update #1
Update #2
CERENKOV MULTI-SPECTRAL IMAGING (CMSI) FOR ADAPTATION AND REAL-TIME IMAGING IN RADIOTHERAPY
Posted 9/2/20
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
CERENKOV MULTI-SPECTRAL IMAGING (CMSI) FOR ADAPTATION AND REAL-TIME IMAGING IN RADIOTHERAPY - PROJECT SUMMARY UNDERSTANDING OF TUMOR MOLECULAR CHARACTERISTICS DURING A COURSE OF RADIOTHERAPY (RT) TREATMENT IS CRUCIAL TO ASSESS THE EFFICACY OF THE TREATMENT AND ADAPT RADIATION DOSAGE TO OPTIMIZE OUTCOMES. UNFORTUNATELY, THIS CANNOT BE ROUTINELY ACHIEVED BY CURRENT DIAGNOSTIC NUCLEAR IMAGING MODALITIES DUE TO COMPLEX LOGISTICS AND PROHIBITIVE COSTS. ALTERNATIVELY, CERENKOV EMISSION (CE) IS AN OPTICAL PHENOMENON THAT ACCOMPANIES EXTERNAL BEAM RADIATION FROM A LINEAR ACCELERATOR AND HAS BEEN DEMONSTRATED FOR IN VIVO DOSIMETRY AND SPECTROSCOPY DURING RADIOTHERAPY. THIS APPROACH SHOWS GREAT POTENTIAL, BUT THE LOW PHOTON RESPONSE FROM COMMERCIALLY AVAILABLE DETECTORS HAS LIMITED ITS IMPACT IN CLINICAL RADIOTHERAPY PRACTICE. THE RECENT DEVELOPMENT OF HIGHLY SENSITIVE, COMPACT SILICON PHOTOMULTIPLIER (SIPM) DEVICES ENABLES ARRAYS OF CE DETECTORS TO BE CUSTOMIZED IN ANY SHAPE AND PLACED DIRECTLY ON A PATIENT'S BODY TO PROVIDE A MUCH ENHANCED SIGNAL, THUS ENABLING CE TO BECOME A NEW, ROUTINE CLINICAL TOOL FOR DAILY MOLECULAR TUMOR CHARACTERIZATION DURING RADIATION TREATMENT. THIS PHASE I STTR WILL ASSESS THE FEASIBILITY OF THIS REVOLUTIONARY CERENKOV MULTI-SPECTRAL IMAGING (CMSI) INNOVATION, WHICH IS THE PRODUCT OF COLLABORATION BETWEEN RESEARCHERS IN THE RADIATION ONCOLOGY AND APPLIED PHYSICS DEPARTMENTS AT THE UNIVERSITY OF MICHIGAN, AND ENDECTRA LLC, A 2015 SPINOUT FROM THE UNIVERSITY OF MICHIGAN WHICH SPECIALIZES IN THE DEVELOPMENT OF NOVEL RADIATION DETECTORS UTILIZING SIPM TECHNOLOGY AND CERENKOV LIGHT ANALYTICS. IN THIS PROJECT, ENDECTRA WILL LEAD SEVERAL ON-BODY SIPM PROBE/ARRAY PROTOTYPING, SCALE-UP, AND TESTING CYCLES, WHILE COLLABORATING RADIATION ONCOLOGY RESEARCHERS PROVIDE DEVICE PERFORMANCE FEEDBACK, ASSESS THE ADVANTAGES OF CMSI OVER OTHER COMMERCIAL APPROACHES, AND TEST THE HYPOTHESIS THAT IMPROVED DETECTION OF CE (AT LOW PHOTON COUNTS) CAN YIELD IMPROVED UTILITY IN REAL-TIME TUMOR MOLECULAR CHARACTERIZATION. SPECIFIC AIMS OF THIS EFFORT INCLUDE THE EVALUATION OF CMSI-SIPM ARRAYS FOR 1) THEIR CAPACITY TO SPECTRALLY PROBE TUMOR MOLECULAR MICROENVIRONMENT AND CALIBRATE THEIR PERFORMANCE IN VITRO USING CELL CULTURE ASSAYS, AND 2) THEIR CAPACITY TO DETERMINE TUMOR AGGRESSIVENESS/RESPONSE AND ASSESS DELIVERED DOSE IN VIVO USING XENOGRAFT MOUSE MODELS. WE EXPECT TO DEMONSTRATE THAT CMSI CAN SIMULTANEOUSLY DETERMINE DELIVERED DOSE WHILE SPECTROSCOPICALLY CHARACTERIZING TUMOR RESPONSE TO RADIOTHERAPY ON A DAILY BASIS AND IN REAL TIME. IF SUCCESSFUL, ENDECTRA COULD PROCEED TO A PHASE II EFFORT INCLUDING HUMAN TRIALS, DEVELOPMENT OF CMSI PROBES FOR MULTIPLE CLINICAL APPLICATIONS, AND DEVELOPMENT OF THE SUBSTANTIAL COMMERCIAL OPPORTUNITY FOR THIS INNOVATION IN THE RADIOTHERAPY EQUIPMENT MARKET. THIS WOULD RESULT IN A PARADIGM SHIFT IN RADIOTHERAPY IMAGE-GUIDANCE, GREATLY IMPROVED PATIENT SAFETY AND THERAPEUTIC IMPACT, AND A MAJOR IMPROVEMENT TO PUBLIC HEALTH.
$0
3/29/22
Not listed
CERENKOV MULTI-SPECTRAL IMAGING (CMSI) FOR ADAPTATION AND REAL-TIME IMAGING IN RADIOTHERAPY - PROJECT SUMMARY UNDERSTANDING OF TUMOR MOLECULAR CHARACTERISTICS DURING A COURSE OF RADIOTHERAPY (RT) TREATMENT IS CRUCIAL TO ASSESS THE EFFICACY OF THE TREATMENT AND ADAPT RADIATION DOSAGE TO OPTIMIZE OUTCOMES. UNFORTUNATELY, THIS CANNOT BE ROUTINELY ACHIEVED BY CURRENT DIAGNOSTIC NUCLEAR IMAGING MODALITIES DUE TO COMPLEX LOGISTICS AND PROHIBITIVE COSTS. ALTERNATIVELY, CERENKOV EMISSION (CE) IS AN OPTICAL PHENOMENON THAT ACCOMPANIES EXTERNAL BEAM RADIATION FROM A LINEAR ACCELERATOR AND HAS BEEN DEMONSTRATED FOR IN VIVO DOSIMETRY AND SPECTROSCOPY DURING RADIOTHERAPY. THIS APPROACH SHOWS GREAT POTENTIAL, BUT THE LOW PHOTON RESPONSE FROM COMMERCIALLY AVAILABLE DETECTORS HAS LIMITED ITS IMPACT IN CLINICAL RADIOTHERAPY PRACTICE. THE RECENT DEVELOPMENT OF HIGHLY SENSITIVE, COMPACT SILICON PHOTOMULTIPLIER (SIPM) DEVICES ENABLES ARRAYS OF CE DETECTORS TO BE CUSTOMIZED IN ANY SHAPE AND PLACED DIRECTLY ON A PATIENT'S BODY TO PROVIDE A MUCH ENHANCED SIGNAL, THUS ENABLING CE TO BECOME A NEW, ROUTINE CLINICAL TOOL FOR DAILY MOLECULAR TUMOR CHARACTERIZATION DURING RADIATION TREATMENT. THIS PHASE I STTR WILL ASSESS THE FEASIBILITY OF THIS REVOLUTIONARY CERENKOV MULTI-SPECTRAL IMAGING (CMSI) INNOVATION, WHICH IS THE PRODUCT OF COLLABORATION BETWEEN RESEARCHERS IN THE RADIATION ONCOLOGY AND APPLIED PHYSICS DEPARTMENTS AT THE UNIVERSITY OF MICHIGAN, AND ENDECTRA LLC, A 2015 SPINOUT FROM THE UNIVERSITY OF MICHIGAN WHICH SPECIALIZES IN THE DEVELOPMENT OF NOVEL RADIATION DETECTORS UTILIZING SIPM TECHNOLOGY AND CERENKOV LIGHT ANALYTICS. IN THIS PROJECT, ENDECTRA WILL LEAD SEVERAL ON-BODY SIPM PROBE/ARRAY PROTOTYPING, SCALE-UP, AND TESTING CYCLES, WHILE COLLABORATING RADIATION ONCOLOGY RESEARCHERS PROVIDE DEVICE PERFORMANCE FEEDBACK, ASSESS THE ADVANTAGES OF CMSI OVER OTHER COMMERCIAL APPROACHES, AND TEST THE HYPOTHESIS THAT IMPROVED DETECTION OF CE (AT LOW PHOTON COUNTS) CAN YIELD IMPROVED UTILITY IN REAL-TIME TUMOR MOLECULAR CHARACTERIZATION. SPECIFIC AIMS OF THIS EFFORT INCLUDE THE EVALUATION OF CMSI-SIPM ARRAYS FOR 1) THEIR CAPACITY TO SPECTRALLY PROBE TUMOR MOLECULAR MICROENVIRONMENT AND CALIBRATE THEIR PERFORMANCE IN VITRO USING CELL CULTURE ASSAYS, AND 2) THEIR CAPACITY TO DETERMINE TUMOR AGGRESSIVENESS/RESPONSE AND ASSESS DELIVERED DOSE IN VIVO USING XENOGRAFT MOUSE MODELS. WE EXPECT TO DEMONSTRATE THAT CMSI CAN SIMULTANEOUSLY DETERMINE DELIVERED DOSE WHILE SPECTROSCOPICALLY CHARACTERIZING TUMOR RESPONSE TO RADIOTHERAPY ON A DAILY BASIS AND IN REAL TIME. IF SUCCESSFUL, ENDECTRA COULD PROCEED TO A PHASE II EFFORT INCLUDING HUMAN TRIALS, DEVELOPMENT OF CMSI PROBES FOR MULTIPLE CLINICAL APPLICATIONS, AND DEVELOPMENT OF THE SUBSTANTIAL COMMERCIAL OPPORTUNITY FOR THIS INNOVATION IN THE RADIOTHERAPY EQUIPMENT MARKET. THIS WOULD RESULT IN A PARADIGM SHIFT IN RADIOTHERAPY IMAGE-GUIDANCE, GREATLY IMPROVED PATIENT SAFETY AND THERAPEUTIC IMPACT, AND A MAJOR IMPROVEMENT TO PUBLIC HEALTH.
$0
3/29/22
Not listed
CERENKOV MULTI-SPECTRAL IMAGING (CMSI) FOR ADAPTATION AND REAL-TIME IMAGING IN RADIOTHERAPY
$327.2k
9/2/20